~~<i id='29E2AC73D7'><strike id='29E2AC73D7'><tt id='29E2AC73D7'><pre id='29E2AC73D7'></pre></tt></strike></i>~~

Home» explore» focus

focus

author：leisure time 2025-09-29 00:12:03 Page View：464

close-up of psoriasis on a hand. -- biotech coverage from STAT — A close-up of psoriasis on a hand. Adobe

San Francisco startup Alumis Inc. has raised $259 million in a bid to best big pharma’s work in plaque psoriasis.

Alumis announced its Series C round Wednesday and plans to move its lead drug into Phase 3 trials. Venture firm Foresite Capital, which incubated Alumis, co-led the financing with Samsara BioCapital and venBio Partners.

Alumis’ lead drug, ESK-001, is an oral medicine designed to help patients with the most common type of psoriasis by inhibiting a signaling protein called TYK2. Research has shown that the TYK2 protein plays a role in diseases where the immune system overreacts, which has made it a popular drug target in recent years.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Advances in CAR
Next article： How to save PrEP access — and even expand it

explore

Peter Hotez and the public health issue of online harassment

AdobeFather’sDayweekendwasanythingbutcalmonTwitter,whicheruptedasvaccineexpertPeterHotezwaschallenge

AstraZeneca chief proposes a novel edit to the drug pricing bill

PascalSoriotofAstraZenecaSTATAmongthepharmaceuticalcompanies’manyobjectionstotheBidenadministration’

Guidelines to prevent youth baseball injuries need more muscle

Apitcheratthe2018LittleLeagueWorldSeries.RobCarr/GettyImages“Weallknowthatweareinthemiddleofanepidem

Ethical issues complicate the benefits of medical crowdfunding

APStockMedicalcrowdfunding—usingsocialnetworksandmediatoraisefundsformedicaltreatment—isgrowinginpop